<![CDATA[Hansa Biopharma - Ny analyse fra Redeye]]>Ny analyse fra Redeye:

Base case SEK 150

Bull case SEK 245

Bear case SEK 100.

https://s3-eu-west-1.amazonaws.com/rdey-cms-prod/app/uploads/2020/05/final-1-91.pdf

]]>https://dev.proinvestor.com/forum/topic/441341/hansa-biopharma-ny-analyse-fra-redeyeRSS for NodeFri, 10 Jul 2026 19:40:56 GMTMon, 11 May 2020 10:07:05 GMT60<![CDATA[Reply to Hansa Biopharma - Ny analyse fra Redeye on Tue, 12 May 2020 10:00:22 GMT]]>Tak for deling.

]]>https://dev.proinvestor.com/forum/post/9459559https://dev.proinvestor.com/forum/post/9459559Tue, 12 May 2020 10:00:22 GMT<![CDATA[Reply to Hansa Biopharma - Ny analyse fra Redeye on Tue, 12 May 2020 06:56:02 GMT]]>Hansa Biopharma - Analyse fra RX Securities

84201_20200429_HNSA___RX_Securities_A_platform_worth_digesting.pdf

]]>https://dev.proinvestor.com/forum/post/9459554https://dev.proinvestor.com/forum/post/9459554Tue, 12 May 2020 06:56:02 GMT<![CDATA[Reply to Hansa Biopharma - Ny analyse fra Redeye on Mon, 11 May 2020 11:07:43 GMT]]>Tak for deling, er selv gået ind for nyligt.

VH
MM

]]>https://dev.proinvestor.com/forum/post/9459555https://dev.proinvestor.com/forum/post/9459555Mon, 11 May 2020 11:07:43 GMT